三生制药PD-1/VEGF双抗早期临床数据公布,展现优效潜力

招银国际
24 Jan

707(PD-1/VEGF)展现优效潜力。三生制药近期公布了707(PD-1/VEGF)的II期临床早期数据:1)在单药一线治疗PD-L1+、EGFR/ALKWTNSCLC的试验中,10mg/kgQ3W剂量组有24例患者经历了至少2次肿瘤评估,ORR达到70.8%,高于依沃西单抗(康方生物,AK112)在Ib期(HARMONi-5,Link)和III期(HARMONi-2,Link)临床试验中的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10